Literature DB >> 266606

Parallel studies of HLA antigens in patients with rheumatic heart disease and scleritis: comparisons with three control populations.

V C Joysey, J H Roger, F Ashworth, W Bullman, B L Hazleman, S M Lachmann, P G Watson.   

Abstract

Parallel studies were carried out on HLA antigens in patients with rheumatic heart disease and scleritis. Comparison with one control population showed a significant excess of BW15 in both disease samples, while a comparison with two other control populations, showed the excess not to be significant. Possible reasons for this discrepancy are discussed, together with the effect on statistical significance of a small percentage of false antigen assignments in one of the samples. A small systematic serological false assignment of an antigen can, by itself, produce a significant result more easily if the frequency of the antigen being detected is low than if it is high. It is suggested that this effect may contribute to the discrepant significant results obtained by different workers in some HLA and disease studies.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 266606

Source DB:  PubMed          Journal:  J Rheumatol Suppl        ISSN: 0380-0903


  4 in total

1.  Clinical features and visual outcomes of scleritis patients presented to tertiary care eye centers in Saudi Arabia.

Authors:  Mohammad Al Barqi; Ashley Behrens; Abdullah M Alfawaz
Journal:  Int J Ophthalmol       Date:  2015-12-18       Impact factor: 1.779

Review 2.  Scleritis and peripheral ulcerative keratitis.

Authors:  Anat Galor; Jennifer E Thorne
Journal:  Rheum Dis Clin North Am       Date:  2007-11       Impact factor: 2.670

Review 3.  Detection of immune complexes in acute rheumatic fever and their relationship to HLA-B5.

Authors:  S Yoshinoya; R M Pope
Journal:  J Clin Invest       Date:  1980-01       Impact factor: 14.808

4.  Association of class II human histocompatibility leukocyte antigens with rheumatic fever.

Authors:  E M Ayoub; D J Barrett; N K Maclaren; J P Krischer
Journal:  J Clin Invest       Date:  1986-06       Impact factor: 14.808

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.